{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:25:18Z","timestamp":1794918318330,"version":"4.9.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.lungcan.2014.08.017","type":"journal-article","created":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T13:15:47Z","timestamp":1409577347000},"page":"133-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9483-6903","authenticated-orcid":false,"given":"Aaron S.","family":"Mansfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Symanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Peikert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2014.08.017_bib0005","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0010","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S1470-2045(11)70307-2","article-title":"The MARS feasibility trial: conclusions not supported by data","volume":"12","author":"Weder","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0015","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/sj.bjc.6605781","article-title":"Projection of mesothelioma mortality in Britain using Bayesian methods","volume":"103","author":"Tan","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0020","series-title":"City in Russia unable to kick asbestos habit","author":"Kramer","year":"2013"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0025","series-title":"Canada stops its defense of asbestos, as Quebec's mines close for good","author":"Chappell","year":"2012"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0030","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(10)60251-6","article-title":"Health experts concerned over India's asbestos industry","volume":"375","author":"Burki","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0035","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0040","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1349-7006.2012.02223.x","article-title":"Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma","volume":"103","author":"Yoshikawa","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0045","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0050","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/oem.2005.023200","article-title":"The French National Mesothelioma Surveillance Program","volume":"63","author":"Goldberg","year":"2006","journal-title":"Occup Environ Med"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0055","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/JTO.0b013e31826915f1","article-title":"Initial analysis of the international association for the study of lung cancer mesothelioma database","volume":"7","author":"Rusch","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0060","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0065","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0070","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1385\/MO:21:4:359","article-title":"Ifosfamide, mesna, and interferon-alpha2A combination chemoimmunotherapy in malignant mesothelioma: results of a single center in central anatolia","volume":"21","author":"Altinbas","year":"2004","journal-title":"Med Oncol"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0075","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabro","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0080","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2012.06.011","article-title":"Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium","volume":"78","author":"Campbell","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0085","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0090","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/bjc.2013.368","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma","volume":"109","author":"Ceresoli","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0095","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.lungcan.2004.08.005","article-title":"Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma","volume":"47","author":"Fennell","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0100","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1097\/JTO.0b013e318260dfb9","article-title":"Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma","volume":"7","author":"Fennell","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0105","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0110","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/JTO.0b013e31818b174d","article-title":"Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study","volume":"3","author":"Hillerdal","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0115","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1752-699X.2008.00050.x","article-title":"Treatment of malignant pleural mesothelioma with liposomized doxorubicine: prolonged time to progression and good survival. A Nordic study","volume":"2","author":"Hillerdal","year":"2008","journal-title":"Clin Respir J"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0120","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cncr.23617","article-title":"Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma","volume":"113","author":"Jackman","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0125","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.lungcan.2007.09.018","article-title":"Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810)","volume":"60","author":"Kalmadi","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0130","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.lungcan.2004.12.002","article-title":"Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B","volume":"48","author":"Kindler","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0135","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0169-5002(00)00166-5","article-title":"Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B","volume":"31","author":"Kindler","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0140","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00001813-200004000-00005","article-title":"Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma \u2013 a feasibility study","volume":"11","author":"Knuuttila","year":"2000","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0145","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/CAD.0b013e32834d7a1c","article-title":"A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma","volume":"23","author":"Kovac","year":"2012","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0150","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2005.04.010","article-title":"Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial","volume":"50","author":"Mathy","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0155","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0169-5002(00)00157-4","article-title":"A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma","volume":"31","author":"Mulatero","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0160","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/sj.bjc.6600505","article-title":"A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma","volume":"87","author":"Nowak","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0165","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma","volume":"7","author":"Nowak","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0170","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1023\/A:1006421706540","article-title":"Phase II study of intravenous doxil in malignant pleural mesothelioma","volume":"18","author":"Oh","year":"2000","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0175","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/cncr.23313","article-title":"A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021","volume":"112","author":"Okuno","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0180","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/1097-0142(20010801)92:3<650::AID-CNCR1366>3.0.CO;2-0","article-title":"Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP)","volume":"92","author":"Parra","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0185","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00000421-200104000-00009","article-title":"Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study","volume":"24","author":"Pinto","year":"2001","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0190","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.lungcan.2004.11.015","article-title":"Raltitrexed\u2013oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients","volume":"48","author":"Porta","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0195","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/JTO.0b013e318191520c","article-title":"Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma","volume":"4","author":"Ramalingam","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0200","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1081\/CNV-120003538","article-title":"Phase II trial of pegylated-liposomal doxorubicin (doxil) in mesothelioma","volume":"20","author":"Skubitz","year":"2002","journal-title":"Cancer Invest"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0205","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1200\/JCO.2000.18.23.3912","article-title":"Phase II study of vinorelbine in patients with malignant pleural mesothelioma","volume":"18","author":"Steele","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2014.08.017_bib0210","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/cncr.11512","article-title":"High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma","volume":"98","author":"Talbot","year":"2003","journal-title":"Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500214003626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500214003626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T00:54:24Z","timestamp":1538268864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500214003626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0169500214003626"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2014.08.017","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2014.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}